Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.

Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.

Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.

Abstract: The present invention concerns the field of stem cell biology, and in particular relates to a method for producing an isolated bona fide population of mammalian stem cells, and uses of the stem cells thus produced. Human glioblastomas (hGBMs) have now been shown to contain a minor subset of cells bearing the defining features of somatic stem cells (SCs) and the ability to establish, expand and perpetuate these tumors. They are defined stem-like tumor propagating cells (TPCs). This has caused a paradigmatic shift in the way we interpret hGBM physiology, for it identifies TPCs as a major culprit to be tackled for the development of novel therapeutics. It also suggests that studying the regulatory mechanisms of normal neurogenesis may point to specific inhibitors of TPCs.

Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.

Abstract: The present invention concerns the field of stem cell biology, and in particular relates to a method for producing an isolated bona fide population of mammalian stem cells, and uses of the stem cells thus produced. Human glioblastomas (hGBMs) have now been shown to contain a minor subset of cells bearing the defining features of somatic stem cells (SCs) and the ability to establish, expand and perpetuate these tumors. They are defined stem-like tumor propagating cells (TPCs). This has caused a paradigmatic shift in the way we interpret hGBM physiology, for it identifies TPCs as a major culprit to be tackled for the development of novel therapeutics. It also suggests that studying the regulatory mechanisms of normal neurogenesis may point to specific inhibitors of TPCs.

Abstract: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.

Abstract: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.